Track topics on Twitter Track topics that are important to you
The purpose of this study is to evaluate efficacy and safety of JNS020QD (fentanyl) in opioid-naive patients with osteoarthritis or low back pain who cannot obtain a sufficient analgesic effect by the treatment of non-opioid analgesics.
JNS020QD (fentanyl) used the same matrix system as that of 3-day fentanyl matrix system but changes every day. This is a multicenter, placebo-controlled, double-blind (neither the patient nor the physician knows the assigned study drug), group-comparison, randomized (patients assigned study drug by chance), withdrawal study. Efficacy and safety of JNS020QD (fentanyl) will be confirmed in opioid-naive patients with osteoarthritis or low back pain that is not sufficiently treated with non-opioid analgesics in the study. Application of JNS020QD (fentanyl) will be started with the 12.5 mcg/hr product, and the dose will not be changed for at least 2 days (about 48 hours) after the initiation of application. The dose of JNS020QD (fentanyl) will be increased by 12.5 mcg/hr at one time if needed, and the maximum dose is to be 50 mcg/hr. Of patients who were transferred to treatment period I and had application of JNS020QD (fentanyl) for 10 to 29 days, those who meet all of the following criteria can be transferred to treatment period II (double-blind period): (1) Patients with a mean VAS score of = 45 mm during 3 days before the end of treatment period I (titration period), (2) Patients with an improvement of > 15 mm in the mean VAS score during 3 days before the end of treatment period I (titration period) compared with that during 3 days before the end of screening period, (3) Patients whose dose of JNS020QD (fentanyl) application is certain during 3 days before the end of treatment period I (titration period), (4) Patients whose number of rescue doses during 3 days before the end of treatment period I (titration period) is <= twice/day. Then, the patients who complete the treatment period I and meet the eligibility criteria for the treatment period II (double-blind period) will be randomly assigned to the JNS020QD (fentanyl) treatment group or placebo treatment group to continue the final application dose in treatment period I (titration period). Application of patches in treatment period II (double-blind period) will be conducted according to the prescribed method based on the final application dose in treatment period I. The study period consists of 3-14 days of screening period, 10-29 days of treatment period I, 12 weeks of treatment period II, 0-2 weeks of tapering period and 1 week of follow up period. The primary end point is time (number of days) from the initial day of patch application in treatment period II to discontinuation due to insufficient analgesic efficacy. The safety evaluations are adverse events, laboratory examinations, vital signs, Electrocardiogram examination, Questionnaire of Opioid Withdrawal Symptoms and Dependence Questionnaire. As pharmacokinetic endpoints, serum fentanyl concentrations are measured. Patients receive initially 12.5 mcg/h of JNS020QD (fentanyl), subsequently the dose of JNS020QD (fentanyl) can be increased up to 50 mcg/h in Period I. The duration of Period I is 10 to 29 days. In Period II (double-blind period), the assigned patch is applied for 12 weeks at the same dose as used at the end of Period I.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Janssen Pharmaceutical K.K.
Published on BioPortfolio: 2014-07-24T14:11:00-0400
The purpose of this study is to evaluate the effectiveness and safety of JNS020 QD(fentanyl) switched from morphine preparations, oral oxycodone preparations, fentanyl citrate injection, o...
The purpose of this study is to evaluate the efficacy and safety of JNS020QD (fentanyl) in opioid-naive patients with post-herpetic neuralgia, comples regional pain syndrome or post-operat...
The purpose of this observational study is to investigate the impact of fentanyl matrix on improvement of pain and functioning in spinal disorder-related chronic pain.
The efficacy of fentanyl TTS for the treatment of neuropathic pain remains to be established, although opioids in general are clearly effective for neuropathic pain and fentanyl TTS has be...
The purpose of this study is to evaluate the usefulness of fentanyl matrix by assessing patients' satisfaction when administrating fentanyl matrix, a background pain treatment, and a break...
Fentanyl rose to prominence as an alternative analgesic to morphine nearly 50 years ago; today, fentanyl has re-emerged as a dangerous recreational substance. The increased potency and analgesic effec...
Fentanyl is an opioid commonly prescribed for cancer pain. Using melanoma-bearing mice, we investigated whether peripheral action would contribute to fentanyl analgesia in cancer pain. Intravenous inj...
Fentanyl is a potent synthetic opioid used as a narcotic analgesic supplement in general and regional anesthesia as well as in management of persistent, severe chronic pain. Alarming epidemiological a...
Morphine delays oral P2Y platelet inhibitor absorption and is associated with adverse outcomes after myocardial infarction. Consequently, many physicians and first responders are now considering fenta...
Despite being reported since 1943 (1) as well as being the subject of a large body of literature since that time, no consensus has been reached regarding the etiology of opioid induced hyperalgesia. I...
A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
A type of pain that is perceived in an area away from the site where the pain arises, such as facial pain caused by lesion of the VAGUS NERVE, or throat problem generating referred pain in the ear.
Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.
Acute pain that comes on rapidly despite the use of pain medication.
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...